NYSE notifies Matinas of listing non-compliance, accepting cure plan

Matinas BioPharma received notice of non-compliance with NYSE American listing standards due to falling below stockholders' equity requirements. The exchange accepted the company's remediation plan, granting a compliance period through October 2027.